Spero Therapeutics, Inc.
NASDAQ:SPROBiotechnology
+$0.08 today
- Market cap
- $50.92M
- Beta
- 1.46
- P/E (TTM)
- 8.2
- EPS (TTM)
- $0.27
Volume 0.27M
Average 0.78M
SPRO Operating Cash Flow
Cash generated by the company's core business operations during the period.
Spero Therapeutics, Inc.NASDAQ: SPRO
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow turns positive
Q1 FY2026 operating cash flow was $15.86M, compared with -$4M a year earlier. Trailing-twelve-month operating cash flow was $7.24M. Over 3 fiscal years it compounded at +17.8% a year.
Context
- Operating cash flow amounted to 21.2% of revenue in FY2025, down 27.7 pp from a year earlier.
- Operating cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly operating cash flow holds near $15.86M or moves back toward the trailing-twelve-month quarterly average of $1.81M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (12.62M) USD
- Year-over-year change
- +46.2%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.62M) | +46.2% |
| FY2024 | 2024-12-31 | (23.44M) | +28.9% |
| FY2023 | 2023-12-31 | (33M) | -326.8% |
| FY2022 | 2022-12-31 | (7.73M) | +88.0% |
| FY2021 | 2021-12-31 | (64.35M) | — |
Operating Cash Flow vs competitors
How SPRO compares with its peers on the latest reported figures
- SPRO's LTM Mar 2026 operating cash flow of $7.24M is the smallest of the 10 companies compared; the peer median is $42.15M.
- Its year-over-year change of +121.7% is the highest of 9, against a peer median of -1.9%.
- Operating cash flow amounts to 13.2% of revenue for SPRO, versus a peer median of 325.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $105.55M | +3.0% | +48.7% | — | |
| LTM Mar 2026 | $83.35M | -18.4% | -25.7% | — | |
| LTM Mar 2026 | $73.64M | +46.6% | +19.8% | — | |
| LTM Mar 2026 | $48.47M | +3.0% | -9.9% | 322.3% | |
| LTM Mar 2026 | $42.15M | -51.2% | — | 3675.1% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $38.99M | +35.1% | — | 325.3% |
| LTM Mar 2026 | $27.3M | — | +54.4% | — | |
| LTM Mar 2026 | $20.25M | -34.9% | +9.9% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $19.78M | -6.8% | +2.6% | — |
| LTM Mar 2026 | $7.24M | +121.7% | +17.8% | 13.2% | |
| Peer median (excluding SPRO) | $42.15M | -1.9% | +9.9% | 325.3% | |
Competitors are the stored peer set for SPRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (89.76M) | (46.42M) | 22.81M | (68.57M) | 8.57M |
| Depreciation & Amortization | 1.12M | 869K | 367K | 2K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.43M | 9.12M | 7.93M | 7.79M | 4.33M |
| Change in Working Capital | 12.86M | 22.09M | (70.38M) | 36.28M | (27.16M) |
| Accounts Receivables | 3.83M | 1.55M | (461K) | (1.54M) | 3.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (53K) | (484K) | 761K | 5.93M | (6.61M) |
| Other Working Capital | 9.08M | 21.02M | (70.68M) | 31.9M | (23.6M) |
| Other Non-Cash Items | 11.43M | 6.61M | 6.28M | 1.04M | 1.64M |
| Operating Cash Flow | (64.35M) | (7.73M) | (33M) | (23.44M) | (12.62M) |
| Capital Expenditures | 64.35M | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 39K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (43.92M) | (26.97M) | 0 | 0 | 0 |
| Sales of Investments | 51.55M | 60.78M | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 7.67M | 33.81M | 0 | 0 | 0 |
| Debt Repayment | 47.48M | (54.49M) | 0 | 0 | 0 |
| Common Stock Issued | 36.57M | 24.93M | 221K | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 84.05M | (29.55M) | 221K | 0 | 0 |
| Effect of Forex Changes | (1) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 27.38M | (3.48M) | (32.77M) | (23.44M) | (12.62M) |
| Free Cash Flow | (64.35M) | (7.73M) | (33M) | (23.44M) | (12.62M) |
Spero Therapeutics, Inc.
NASDAQ:SPRO
Intrinsic Alpha fair value
Locked
Current Price
$0.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.